Skip to Content Skip to Search

GSK statement on UK Government-initiated review of antibiotic resistance

We welcome today’s announcement of a review to explore the economic issues surrounding antimicrobial resistance. This is a positive step towards addressing this global public health threat.

"We welcome today’s announcement of a review to explore the economic issues surrounding antimicrobial resistance. This is a positive step towards addressing this global public health threat.

GSK has a 40 year heritage in this field and is one of only a handful of companies still conducting R&D into antibiotics.  

This is a very complex area and new approaches are needed if more companies are to be encouraged to invest in this area.  This needs to include new economic models and more open-minded approaches to sharing information and working with partners across the public and private sectors."

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2013.